Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Klarna Group plc, focusing on whether Klarna and its executives made materially false or misleading statements regarding the company's business and operations [1][2]. Company Overview - Klarna provides payment, advertising, and digital retail banking solutions to consumers and merchants [2]. Investigation Details - The investigation by Robbins Geller is centered on potential misleading statements or omissions of material information by Klarna and its top executives [2]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone, which is more than the next five law firms combined [3]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors [3]. - Robbins Geller has a significant history of obtaining large securities class action recoveries, including the largest ever at $7.2 billion in the Enron case [3].

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Alexand ...

INSP COURT ALERT: Inspire Medical Systems, Inc. Investors are Notified the Company has been Sued for Securities Fraud and are Notified to Contact BFA Law by January 5December 02, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 2, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for se ...

Core Viewpoint - A federal securities class action has been filed against Jayud Global Logistics Limited, alleging misleading statements and a "pump-and-dump" scheme involving its Class A ordinary shares during the class period from April 21, 2023, to April 30, 2025 [1][2]. Group 1: Legal Action Details - The class action is filed in the United States District Court for the Southern District of New York [1]. - Investors have until January 20, 2026, to seek appointment as lead plaintiff in the case [3]. Group 2: Allegations Against Jayud - The complaint alleges that Jayud and other defendants made materially false or misleading statements and failed to disclose adverse facts [2]. - The defendants are accused of being "uniquely situated" to orchestrate a pump-and-dump scheme involving Jayud's shares [2]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, founded in 1888, has over 125 years of legal expertise in securities litigation and aims to protect the rights of investors [3].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [4]. - Investors have until December 23, 2025, to request to be appointed to lead the case [4]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [5]. Group 3: Allegations of Misrepresentation - During the relevant period, James Hardie claimed that its North American fiber cement segment showed "inherent strength" and "underlying momentum," while in reality, sales were driven by inventory loading rather than sustainable customer demand [6]. - The company reported a 12% decline in North American fiber cement sales during the quarter, revealing that customers were destocking to return to normal inventory levels [7]. Group 4: Stock Performance - Following the revelation of declining sales, James Hardie's stock price fell by $9.79 per share, a decrease of over 34%, from $28.43 on August 19, 2025, to $18.64 on August 20, 2025 [7]. Group 5: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [8].

INSP SHAREHOLDERS: Inspire Medical Systems, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by January 5December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud ...

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging significant accounting irregularities and misleading disclosures that resulted in inflated profits and concealed losses [1][3]. Summary by Sections Lawsuit Announcement - Berger Montague PC has announced a class action lawsuit on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. Allegations - The lawsuit claims that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to hide losses and inflate profits [3][4]. - Specific allegations include a fabricated $17 million receivable, a subsidiary's profits inflated by 150%, and a significant discrepancy in asset valuation, where an asset valued at $14.9 million was sold for only $2.5 million weeks later [4]. Financial Impact - Following the release of the NINGI Research report, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31, indicating substantial investor losses [5].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance - Beyond Meat announced a non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was expected to be material [4]. - The company reported losses from operations of $112.3 million for 3Q 2025, which included $77.4 million in non-cash impairment charges [5]. Stock Market Reaction - Following the announcement of the expected impairment charge on October 24, 2025, Beyond Meat's stock price dropped approximately 23%, from $2.84 per share to $2.185 per share [4]. - The delay in the earnings announcement for 3Q 2025 on November 3, 2025, further contributed to a significant decline in the stock price during that trading day [5].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].